enoblituzumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| type = mab

| image =

| alt =

| mab_type =

| source = zu/o

| target = B7-H3

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1353485-38-7

| UNII = M6030H73N9

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank =

| KEGG = D11752

| ChemSpiderID = none

| C=6474 | H=9990 | N=1726 | O=2030 | S=42

| synonyms = MGA271

}}

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[http://www.ama-assn.org/resources/doc/usan/x-pub/enoblituzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab], American Medical Association. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.